keratin.com, hair loss, baldness, alopecia, disease, and treatment information

anagen effluvium

Hair Biology
Diagnosis / Decisions
Androgenetic Alopecia Biology
Androgenetic Alopecia Clinical Patterns
Androgenetic Alopecia Treatments
Hair Restoration
Alopecia Areata
Effluviums
Scarring Alopecias
Inflammatory Alopecias
Other Alopecias
Hair Shaft Defects
Infectious Hair Disease
Hirsutism / Hypertrichosis
Hair Color
Hair Cosmetics
Bits and Pieces
Immunology
Discussion Forums
Personal / Site Information
  • Anagen effluvium
  • Potential causes of anagen effluvium overview
  • Anagen effluvium references

  • Anagen effluvium

    Anagen effluvium is a generalized diffuse hair loss from follicles in the anagen growth phase with quite rapid development 1-4 weeks after the initial trigger. Hair loss can be quite extensive as it affects all follicles in an anagen stage of active growth and around 90% of the average person's hair follicles are at this stage at any one time. Anagen effluvium results from the simultaneous inhibition of cell division in hair follicles leading to a sudden stop in hair fiber production.

    As with telogen effluvium, anagen effluvium can be caused by a wide range of triggers. Most significantly, some trigger factors may promote anagen effluvium and telogen effluvium, even within the same individual. This is a point worth noting when you read through the summary list of trigger factors for anagen effluvium below.

    Anagen effluvium can be induced by poisoning with arsenic or thallium salts and other similar substances. Anagen effluvium may be observed as part of a larger medical hair loss condition such as alopecia areata. However, extensive anagen effluvium is most often seen in people undergoing chemotherapy as a cancer treatment. The whole point of cancer treatment is to slow down or stop rapidly dividing cells. This is good when trying to stop the development of tumors but hair follicles are also regions of very rapidly dividing cells. These cells produce the hair fiber and are some of the fastest dividing cells in the body that are not cancerous. Chemotherapy takes a shot gun approach by universally blocking rapid cell division regardless of whether the cells are actually cancerous or not.


    Potential causes of anagen effluvium overview

    There are many potential causes of anagen effluvium. More common causes are listed below and some are explained in greater detail elsewhere.

    • Genetic hereditary disease - Pollitt's syndrome, Marie Unna type hypotrichosis
    • Defective hormone production - Anagen effluvium may be associated with hypopituitarism (hypopituitary dwarfism, Simmond's disease, Sheehan's syndrome), thyroid gland defects (hypothyroidism, hyperthyroidism), Cushing's syndrome, and occasionally juvenile diabetes
    • Nutrient deficiencies - Extreme deficiency of copper, iron, zinc, biotin, essential fatty acids, or vitamin C in the diet may lead to anagen effluvium
    • Cancer treatments - Drug categories such as cytostatic drugs, alkylating drugs, and antimetabolic drugs cause anagen effluvium
    • Ionizing radiation - X rays and gamma rays
    • Toxic agents - Thallium, arsenic, lead, bismuth, vitamin A and derivative drugs


    Anagen effluvium references

    • Sommer M, Wilson C. Therapeutic approaches to the management of common baldness. Int J Clin Pract. 1999 Jul-Aug;53(5):381-5.
    • Tosi A, Misciali C, Piraccini BM, Peluso AM, Bardazzi F. Drug-induced hair loss and hair growth. Incidence, management and avoidance. Drug Saf. 1994 Apr;10(4):310-7.
    • Peter RU, Braun-Falco O, Birioukov A, Hacker N, Kerscher M, Peterseim U, Ruzicka T, Konz B, Plewig G. Chronic cutaneous damage after accidental exposure to ionizing radiation: the Chernobyl experience. J Am Acad Dermatol. 1994 May;30(5 Pt 1):719-23.
    • Modan B, Alfandary E, Shapiro D, Lusky A, Chetrit A, Shewach-Millet M, Movshovitz M. Factors affecting the development of skin cancer after scalp irradiation. Radiat Res. 1993 Jul;135(1):125-8.
    • Schauer DA, Coursey BM, Dick CE, McLaughlin WL, Puhl JM, Desrosiers MF, Jacobson AD. A radiation accident at an industrial accelerator facility. Health Phys. 1993 Aug;65(2):131-40.
    • Headington JT. Telogen effluvium. New concepts and review. Arch Dermatol. 1993 Mar;129(3):356-63.
    • Berth-Jones J, Shuttleworth D, Hutchinson PE. A study of etretinate alopecia. Br J Dermatol. 1990 Jun;122(6):751-5.
    • Gollnick H, Blume U, Orfanos CE. [Adverse drug reactions on hair]. Z Hautkr. 1990 Dec;65(12):1128-34.
    • Lancaster J. About radiotherapy--Part II. Side effects and staff protection. Nurs RSA. 1989 Mar;4(3):41-3.
    • Spencer LV, Callen JP. Hair loss in systemic disease. Dermatol Clin. 1987 Jul;5(3):565-70.
    • Messenger AG, Slater DN, Bleehen SS. Alopecia areata: alterations in the hair growth cycle and correlation with the follicular pathology. Br J Dermatol. 1986 Mar;114(3):337-47.
    • Albert RE, Omran AR, Brauer EW, Cohen NC, Schmidt H, Dove DC, Becker M, Baumring R, Baer RL. Follow-up study of patients treated by x-ray epilation for tinea capitis. II. Results of clinical and laboratory examinations. Arch Environ Health. 1968 Dec;17(6):919-34.

    Top of the page

    Copyright ©. All Rights Reserved
    http://www.keratin.com
    Top of the page